Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making
BackgroundThe current drug development paradigm has been criticized for being too drug-centered and for not adequately focusing on the patients who will eventually be administered the therapeutic interventions it generates. The drug-driven nature of the present framework has led to the emergence of...
Saved in:
Main Authors: | Robbe Saesen (Author), Stéphane Lejeune (Author), Gianluca Quaglio (Author), Denis Lacombe (Author), Isabelle Huys (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
by: Robbe Saesen, et al.
Published: (2022) -
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
by: Stefanie Broes, et al.
Published: (2021) -
Patients' knowledge, preferences, and perspectives about data protection and data control: an exploratory survey
by: Teodora Lalova-Spinks, et al.
Published: (2024) -
Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders
by: M Dooms, et al.
Published: (2022) -
How to balance valuable innovation with affordable access to medicines in Belgium?
by: Steven Simoens, et al.
Published: (2022)